- Home
- ACIW vs IONS Comparison
ACIW vs IONS Comparison
Compare ACIW & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIW
- IONS
- Stock Information
- Founded
- ACIW 1975
- IONS 1989
- Country
- ACIW United States
- IONS United States
- Employees
- ACIW N/A
- IONS N/A
- Industry
- ACIW EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIW Technology
- IONS Health Care
- Exchange
- ACIW Nasdaq
- IONS Nasdaq
- Market Cap
- ACIW 5.6B
- IONS 4.6B
- IPO Year
- ACIW 1995
- IONS 1991
- Fundamental
- Price
- ACIW $50.94
- IONS $28.40
- Analyst Decision
- ACIW Buy
- IONS Buy
- Analyst Count
- ACIW 5
- IONS 18
- Target Price
- ACIW $53.33
- IONS $57.00
- AVG Volume (30 Days)
- ACIW 844.2K
- IONS 2.0M
- Earning Date
- ACIW 04-29-2025
- IONS 04-30-2025
- Dividend Yield
- ACIW N/A
- IONS N/A
- EPS Growth
- ACIW 70.55
- IONS N/A
- EPS
- ACIW 1.91
- IONS N/A
- Revenue
- ACIW $1,594,288,000.00
- IONS $705,138,000.00
- Revenue This Year
- ACIW $8.58
- IONS N/A
- Revenue Next Year
- ACIW $7.16
- IONS $25.80
- P/E Ratio
- ACIW $26.67
- IONS N/A
- Revenue Growth
- ACIW 9.76
- IONS N/A
- 52 Week Low
- ACIW $31.19
- IONS $23.95
- 52 Week High
- ACIW $59.71
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- ACIW 45.00
- IONS 44.54
- Support Level
- ACIW $49.70
- IONS $27.57
- Resistance Level
- ACIW $53.13
- IONS $29.04
- Average True Range (ATR)
- ACIW 2.78
- IONS 1.79
- MACD
- ACIW -0.20
- IONS 0.12
- Stochastic Oscillator
- ACIW 37.56
- IONS 68.15
About ACIW ACI Worldwide Inc.
ACI Worldwide Inc develops, markets and installs a portfolio of software products focused on facilitating electronic payments. The firm also leverages its distribution network in the Americas; Europe, the Middle East, and Africa, or EMEA; and Asia-Pacific regions to sell software developed by third parties. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but majority of the revenue is generated in the United States and EMEA regions.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.